Preventive Services

Interim Final Rules for Non-Grandfathered Group Health Plans and Health Insurance Issuers Coverage of Preventive Services Under the Patient Protection and Affordable Care Act

Introduction

Public Health Service (PHS) Act section 2713 and the interim final regulations require non-grandfathered group health plans and health insurance coverage offered in the individual or group market to provide benefits for and prohibit the imposition of cost-sharing requirements for the following (with respect to the individual involved):

- Evidenced-based items or services that have in effect a rating of “A” or “B” in the current recommendations of the U.S. Preventive Services Task Force (USPSTF)
- Immunizations for routine use in children, adolescents and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC)
- For infants, children and adolescents, evidence-informed preventive care and screenings provided for, in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA)
- For women, evidence-informed preventive care and screening provided for in the comprehensive guidelines supported by HRSA, to the extent not already included in certain recommendations of the USPSTF

Below are CVS Caremark® recommendations for coverage of preventive services without cost-sharing requirements. These preventive services recommendations may not be covered under all formularies and plan designs. Please note: An exception process must be available for clinical circumstances that fall outside the recommended coverage (e.g., a request for coverage of a brand-name medication because the available generic medications are not medically appropriate). A process is also available for coverage of preventive services without cost sharing for plan members identifying with a gender that differs from the member’s sex assigned at birth (e.g., a request for coverage of contraceptives or primary prevention of breast cancer for transgender members).

Aspirin

Aspirin to Prevent Cardiovascular Disease (CVD) and Colorectal Cancer (CRC)
The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.

CVS Caremark Recommendation
- Age limit 50 to 59 years (men and women)
- No prior authorization
- Quantity limit of 100 units per fill
- Generic only
- Over-the-counter (OTC) (requires prescription)

Generic Product Identifier (GPI) Description*
Single ingredient: All oral dosage forms 81 mg
Includes dosage forms such as:
- Aspirin chew tab 81 mg
- Aspirin enteric coated tab 81 mg

Please note: Effective January 1, 2023, this program will be removed from the ACA preventive services coverage and will revert back to standard benefit design.

*See disclaimer on last page for more information.
## Aspirin

### Aspirin to Prevent Morbidity and Mortality from Preeclampsia: Women

The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members capable of pregnancy</td>
<td>Single ingredient: All oral dosage forms 81 mg</td>
</tr>
<tr>
<td>• Age limit 12 to 59 years</td>
<td>Includes dosage forms such as:</td>
</tr>
<tr>
<td>• No prior authorization</td>
<td>• Aspirin chew tab 81 mg</td>
</tr>
<tr>
<td>• Quantity limit of 100 units per fill</td>
<td>• Aspirin enteric coated tab 81 mg</td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
<tr>
<td>• OTC (requires prescription)</td>
<td></td>
</tr>
</tbody>
</table>

### Oral Fluorides

### Chemoprevention of Dental Caries (Cavities)

The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation at currently recommended doses to preschool children older than six months of age whose primary water source is deficient in fluoride.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age limit ≤ five years</td>
<td>Single ingredient: Oral dosage forms ≤ 0.5 mg</td>
</tr>
<tr>
<td>• No prior authorization</td>
<td>• Sodium fluoride chew tab 0.25 mg – 0.5 mg</td>
</tr>
<tr>
<td>• No quantity limit</td>
<td>• Sodium fluoride soln 0.125 mg/drop &amp; 0.25 mg/drop</td>
</tr>
<tr>
<td>• Brand and generic</td>
<td>• Sodium fluoride soln 0.25 mg/0.6 mL</td>
</tr>
<tr>
<td>• Rx products only</td>
<td>• Sodium fluoride soln 0.5 mg/mL</td>
</tr>
<tr>
<td></td>
<td>• Sodium fluoride tab 0.5 mg</td>
</tr>
</tbody>
</table>

### Folic Acid

### Supplementation with Folic Acid

The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 mg to 0.8 mg (400 mcg to 800 mcg) of folic acid.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members capable of pregnancy</td>
<td>Single ingredient</td>
</tr>
<tr>
<td>• Age limit ≤ 55</td>
<td>• Folic acid cap 0.8 mg</td>
</tr>
<tr>
<td>• No prior authorization</td>
<td>• Folic acid tab 0.4 mg &amp; 0.8 mg</td>
</tr>
<tr>
<td>• Quantity limit 100 units per fill</td>
<td></td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
<tr>
<td>• OTC (requires prescription)</td>
<td></td>
</tr>
</tbody>
</table>

*See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
**Tobacco Cessation**

**Adults Who Are Not Pregnant**
The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)-approved pharmacotherapy for cessation to adults who use tobacco.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• No prior authorization of tobacco cessation products</td>
<td>• Bupropion HCl tab SR 12hr 150 mg</td>
</tr>
<tr>
<td>• Limit of 168-day supply of each product in one year of treatment</td>
<td>• Nicotine TD patch 24 hr 21 mg, 14 mg &amp; 7 mg</td>
</tr>
<tr>
<td>• Coverage includes generic nicotine replacement products (nicotine patch, gum and lozenges), brand Nicotrol (inhaler system), brand Nicotrol NS (nasal spray), generic and brand Chantix/Varenicline and generic Zyban</td>
<td>• Nicotine polacrilex gum 2 mg &amp; 4 mg</td>
</tr>
<tr>
<td>• Generics and single-source brands</td>
<td>• Nicotine polacrilex lozenge 2 mg &amp; 4 mg</td>
</tr>
</tbody>
</table>
| • Brands until generics become available | • Nicotine inhaler system 10 mg (4 mg delivered)  
  － Nicotrol brand |  
| • Rx or OTC (requires prescription) | • Nicotine nasal spray 10 mg/mL (0.5 mg/spray)  
  － Nicotrol NS brand |
|  | • Varenicline tartrate tab 0.5 mg (base equiv) & 1 mg (base equiv)  
  － Chantix/Varenicline brand |
|  | • Varenicline tartrate tab 0.5 mg X 11 tabs & 1 mg X 42 pack |

**Immunizations**

**Immunizations: Vaccines**
The USPSTF recommends immunizations for routine use in children, adolescents and adults that are recommended by the Advisory Committee on Immunization Practices of the CDC on the CDC Immunization Schedules.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
</table>
| • Children – birth through age 18 | • COVID-19 (recommended ages and populations vary)¹ | Doses, recommended ages and recommended populations vary:  
  • COVID-19¹ |  
| • Adults – covered age ≥ 19 | • Dengue (**effective 12/1/22**)  
  • Diphtheria, Tetanus, Pertussis  
  • Haemophilus Influenzae Type B  
  • Hepatitis A  
  • Hepatitis B  
  • Human Papillomavirus  
  • Inactivated Poliovirus  
  • Influenza  
  • Measles, Mumps, Rubella  
  • Meningococcal  
  • Pneumococcal  
  • Rotavirus  
  • Varicella | • Hepatitis A  
  • Hepatitis B  
  • Herpes Zoster  
  • Human Papillomavirus  
  • Influenza  
  • Measles, Mumps, Rubella  
  • Meningococcal  
  • Pneumococcal  
  • Tetanus, Diphtheria, Pertussis  
  • Varicella |
| • Rx only | • |  
| • Plans may choose to cover vaccines under the medical or pharmacy benefit | • |  
| • If plans cover under the pharmacy benefit any vaccines which appear on the Immunization Schedules of the CDC, then the non-grandfathered or new start plans should apply $0 copay for these vaccines**  
  [CDC.gov/vaccines/schedules](https://www.cdc.gov/vaccines/schedules) | • |  
| • No prior authorization | • |  

---

¹ Covered for populations recommended by the CDC at the time of administration. Subject to state allocation guidelines and availability. During the United States public health emergency, covered for clients opting into the CVS Caremark COVID-19 Vaccine Program only.  
*See disclaimer on last page for more information.  
**For a complete listing of product names, contact your account representative.  
©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
## Bowel Preparation Medications

### Screening for Colorectal Cancer

The USPSTF recommends screening for colorectal cancer (CRC) using fecal occult blood testing, sigmoidoscopy or colonoscopy, in adults, beginning at age 45 years and continuing through age 75 years.

Since colonoscopy is an option for screening, and adequate bowel preparation is required prior to the procedure, coverage of medications that will provide adequate preparation should be provided.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age limit 45 through 75 years (men and women)</td>
<td>• CLENPIQ</td>
</tr>
<tr>
<td>• No prior authorization or quantity limits</td>
<td>• PEG-PREP KIT</td>
</tr>
<tr>
<td>• Rx only</td>
<td>• PLENVU</td>
</tr>
<tr>
<td>• Generics and single-source brands</td>
<td>• SUTAB</td>
</tr>
<tr>
<td>• Generics are in <em>italics</em>. Brand-name products are CAPITALIZED</td>
<td>• <em>Polyethylene glycol-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid</em></td>
</tr>
<tr>
<td>• Brands until generics become available</td>
<td>• Sodium sulfate, potassium sulfate and magnesium sulfate</td>
</tr>
</tbody>
</table>

## Statins

### Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

The USPSTF recommends that adults without a history of CVD (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all the following criteria are met:

1) they are aged 40 to 75 years
2) they have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension or smoking)
3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age limit 40 to 75 years (men and women)</td>
<td>Generic low to moderate intensity statins</td>
</tr>
<tr>
<td>• No prior authorization</td>
<td>Includes the following strengths:</td>
</tr>
<tr>
<td>• No quantity limit</td>
<td>• Atorvastatin 10 mg, 20 mg</td>
</tr>
<tr>
<td>• Generic only</td>
<td>• Fluvastatin 20 mg, 40 mg</td>
</tr>
<tr>
<td>• Only low to moderate intensity statins</td>
<td>• Fluvastatin ER 80 mg</td>
</tr>
<tr>
<td>• Rx</td>
<td>• Lovastatin 10 mg, 20 mg, 40 mg</td>
</tr>
</tbody>
</table>

*See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G  093022
## Preexposure Prophylaxis

### Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (PrEP)

The USPSTF recommends that clinicians offer PrEP with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Preventive use only</td>
<td>• Emtricitabine/tenofovir disoproxil fumarate 200 mg-300 mg</td>
</tr>
<tr>
<td>• Quantity limit (1 tab/day)</td>
<td></td>
</tr>
<tr>
<td>• Rx</td>
<td></td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
</tbody>
</table>

## Diabetes Prevention

### Screening for Prediabetes and Type 2 Diabetes

The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Preventive use only</td>
<td>• Metformin 850 mg</td>
</tr>
<tr>
<td>• Age 35 to 70 years</td>
<td></td>
</tr>
<tr>
<td>• No prior authorization</td>
<td></td>
</tr>
<tr>
<td>• No quantity limit</td>
<td></td>
</tr>
<tr>
<td>• Generic only</td>
<td></td>
</tr>
<tr>
<td>• Rx</td>
<td></td>
</tr>
</tbody>
</table>

*See disclaimer on last page for more information.*

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
Women’s Preventive Services

Introduction
On August 1, 2011, the Department of Health and Human Services (HHS) adopted Guidelines for Women’s Preventive Services—including well-woman visits, support for breast feeding equipment, contraception and domestic violence screening—that will be covered without cost sharing in non-grandfathered health plan years starting on or after August 1, 2012. The guidelines were recommended by the independent Institute of Medicine (IOM) and based on scientific evidence.

Oral Contraceptives

The IOM Recommended as a Preventive Service for Women
The full range of U.S. FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.\(^2\)

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members capable of pregnancy</td>
</tr>
<tr>
<td>• Rx</td>
</tr>
<tr>
<td>• Generics and single-source brands</td>
</tr>
<tr>
<td>• Brands until generics become available</td>
</tr>
</tbody>
</table>

Product Description*
Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/RED)* have no generic available and are recommended for coverage.

EE=Ethinyl Estradiol

HIGH-DOSE MONOPHASIC PILLS

| • EE 50 mcg/Ethynodiol diacetate 1 mg *(Ethynodiol 1/50, Kelnor 1/50)* |

---

2. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

*See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G  093022
### Oral Contraceptives

#### BIPHASIC PILLS
- EE 20 mcg/Desogestrel 0.15 mg (Azurette, Kariva, Mircette, Pimtrea, Simliya, Viorele, Volnea)

#### LOW-DOSE MONOPHASIC PILLS
- EE 20 mcg/Drospirenone 3 mg (Jasmiel, Lo-Zumandimine, Loryna, Nikki, Vestura, Yaz)
- EE 20 mcg/Drospirenone 3 mg + Calcium 0.451 mg (Beyaz)
- EE 20 mcg/Levonorgestrel 0.1 mg (Afirmelle, Aubra, Aubra EQ, Aviane-28, Delyla, Falmina, Lessina, Lutera, Sronyx, Vienva)
- **TYBLUME** (EE 20 mcg/Levonorgestrel 0.1 mg)
- **BALCOLTRA** (EE 20 mcg/Levonorgestrel 0.1 mg/FE)
- EE 20 mcg/Norethindrone 1 mg and/FE (Aurovela 1/20, Aurovela 24 FE, Aurovela FE 1/20, Blisovi 24 FE, Blisovi FE 1/20, Hailey 24 FE, Hailey FE 1/20, Junel 1/20, Junel 24 FE, Junel FE 1/20, Larin 1/20, Larin 24 FE, Larin FE 1/20, Loestrin 1/20-21, Loestrin FE 1/20, Microgestin 1/20, Microgestin 24 FE, Microgestin FE 1/20, Tarina 24 FE, Tarina FE 1/20 EQ)
- EE 20 mcg/Norethindrone 1 mg/FE (Charlotte 24 FE, Finzala FE, Minastrin 24 FE)
- EE 20 mcg/Norethindrone 1 mg/FE (Gemmily, Merzee, Taysofy, Taytulla)
- EE 25 mcg/Norethindrone 0.8 mg/FE (Generess FE, Kaitlib FE, Layolis FE)
- EE 30 mcg/Levonorgestrel 0.15 mcg (Altavera, Ayuna, Chateal, Chateal EQ, Kurvelo, Levora, Marlissa, Portia-28)
- EE 30 mcg/Norgestrel 0.03 mg (Cryselle-28, Elinest, Low-Ogestrel)
- EE 30 mcg/Norethindrone acetate 1.5 mg and/FE (Aurovela 1.5/30, Aurovela FE 1.5/30, Blisovi 1.5/30, Hailey 1.5/30, Junel 1.5/30, Junel FE 1.5/30, Larin 1.5/30, Loestrin 1.5/30 -21, Loestrin FE 1.5/30, Microgestin 1.5/30, Microgestin FE 1.5/30)
- EE 30 mcg/Desogestrel 0.15 mg (Apri, Cyred, Cyred EQ, Emoquette, Enskyce, Isibloom, Juleber, Kalliga, Reclipsen)
- EE 30 mcg/Drospirenone 3 mg (Ocella, Syeda, Yasmin, Zumandimine)
- EE 35 mcg/Ethynodiol diacetate 1 mg (Kelnor 1/35, Zovia 1/35)
- EE 35 mcg/Norgestimate 0.25 mg (Estarylla, Femynor, Miles, Mono-linyah, Nymyo, Sprintec, Vylibra)
- EE 35 mcg/Norethindrone 0.4 mg and/FE (Balziva-28, Briellyn, Philith, Vyfemla, Wymzya FE)
- EE 35 mcg/Norethindrone 0.5 mg (Necon 0.5/35, Nortrel 0.5/35, Wera)
- EE 35 mcg/Norethindrone 1 mg (Alyacen 1/35, Dasetta 1/35, Nortrel 1/35, Nyla 1/35, Pirmella 1/35)
- EE 30 mcg/Drospirenone 3 mg + Calcium 0.451 mg (Safyral, Tydemy)
- **NESTSTELLIS** (Estetrol 14.2 mg/Drospirenone 3 mg)

#### TRIPHASIC PILLS
- EE 20 mcg, 30 mcg, 35 mcg/Norethindrone 1 mg (Estrostep FE, Tilia Fe, Tri-Legest FE)
- EE 25 mcg/Desogestrel 0.1 mg, 0.125, 0.15 mg (Velivet)
- EE 25 mcg/Norgestimate 0.18 mg, 0.215 mg, 0.25 mg (Tri-Lo Estarylla, Tri-Lo Marzia, Tri-Lo-Mili, Tri-Lo-Sprintec, Tri-Vylibra Lo)
- EE 30 mcg, 40 mcg, 30 mcg/Levonorgestrel 0.05 mg, 0.075 mg, 0.125 mg (Enpresse, Levonest, Trivora)
- EE 35 mcg/Norethindrone 0.5 mg, 1 mg, 0.5 mg (Aranelle, Leena)
- EE 35 mcg/Norethindrone 0.5 mg, 0.75 mg, 1 mg (Alyacen 7/7/7, Dasetta 7/7/7, Nortrel 7/7/7, Nylia 7/7/7, Pirmella 7/7/7)
- EE 35 mcg/Norgestimate 0.18 mg, 0.215 mg, 0.25 mg (Tri-Estarylla, Tri-Femynor, Tr-Lo-Mili, Tr-Mili, TriNessa, Tr-Lo-Mili, Tri-Vylibra)

*See disclaimer on last page for more information.*
Oral Contraceptives

FOUR-PHASIC
- **NATAZIA** (Estradiol valerate/Dienogest)

EXTENDED – CYCLE PILLS
- **LO LOESTRIN FE** (EE 10 mcg/Norethindrone 1 mg)
- EE 10, 20, 25, 30 mcg/Levonorgestrel 0.15 mg (Fayosim, Quartette, Rivelsa)
- EE 20, 10 mcg/Levonorgestrel 0.1 mg (Camrese Lo, LoJaimiess, LoSeasonique)
- EE 30 mcg/Levonorgestrel 0.15 mg (Iclevia, Introval, Jolessa, Setlakin)
- EE 30, 10 mcg/Levonorgestrel 0.15 mg (Amethia, Ashlyna, Camrese, Daysee, Jaimiess, Seasonique, Simpesse)

CONTINUOUS – CYCLE PILLS
- EE 20 mcg/Levonorgestrel 90 mcg (Amethyst, Dolishale)

PROGESTIN-ONLY PILLS “Mini-Pills”
- Norethindrone 0.35 mg (Camila, Deblitane, Errin, Heather, Incassia, Jencycla, Lyleq, Lyza, Nora-BE, Norlyroc, Ortho Micronor, Sharobel)
- **SLYND** (Drospirenone 4 mg)

Emergency Contraceptives

The IOM Recommended as a Preventive Service for Women

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.¹

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

**CVS Caremark Recommendation**
- Females or members capable of pregnancy
- Rx
- OTCs (requires prescription)

**Product Description**
Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in **(BOLD/RED)** have no generic available and are recommended for coverage.

- Levonorgestrel 1.5 mg tablet (*AfterPill, Aftera, Plan B, Econtra EZ, Econtra OS, My Choice, My Way, New Day, Opicon, Option 2, Take Action, React*)
- **ELLA** (Ulipristal 30 mg tablet) (progesterone receptor modulator)

---

¹ Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
Injectables

The IOM Recommended as a Preventive Service for Women

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.\(^2\)

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

### CVS Caremark Recommendation

- Females or members capable of pregnancy
- Rx
- Quantity limit
  - 1 injection/75 days or 4 injections/300 days
- Brands until generics become available

### Product Description*

Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in **(BOLD/RED)** have no generic available and are recommended for coverage.

- Medroxyprogesterone acetate 150 mg IM x q3 months *(Depo-Provera)*
- DEPO-SUBQ-PROVERA 104 *(Medroxyprogesterone acetate 104 mg SQ X q3 months)*

---

**Miscellaneous—Intrauterine Devices, Subdermal Rods & Vaginal Rings**

### The IOM Recommended as a Preventive Service for Women

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.\(^2\)

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

### CVS Caremark Recommendation

- Females or members capable of pregnancy
- Rx
- Plans may choose to cover these items under the medical or pharmacy benefit
- Quantity limits
  - Intrauterine Device (IUD) (1/300 days)
  - Sub-dermal Rod (1/300 days)
  - Vaginal Ring (13/300 days)
  - Vaginal System (1/300 days)

---

\(^2\) Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

*See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
**Miscellaneous—Intrauterine Devices, Subdermal Rods & Vaginal Rings**

**Product Description***
Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in **(BOLD/RED)** have no generic available and are recommended for coverage.

- **KYLEENA** IUD (Levonorgestrel 19.5 mcg/day)
- **LILETTA** IUD (Levonorgestrel 18.6 mcg/day)
- **MIRENA** IUD (Levonorgestrel 20 mcg/day)
- **PARAGARD T 380A** IUD (Copper 309 mg/day)
- **SKYLA** IUD (Levonorgestrel 13.5 mcg/day)
- **NEXPLANON** Subdermal Rod (Etonogestrel 68 mg – release rate varies over time)
- Ethinyl estradiol 15 mcg/Etonogestrel 120 mcg vaginal ring *(EluRyng, NuvaRing)*
- **ANNOVERA** Vaginal System (Ethinyl estradiol 17.4 mg/Segesterone acetate 103 mg)

**Transdermal Patch**

**The IOM Recommended as a Preventive Service for Women**
The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.²

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>Product Description***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females or members capable of pregnancy</td>
<td>Brand names in <em>italics</em> and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in <strong>(BOLD/RED)</strong> have no generic available and are recommended for coverage.</td>
</tr>
<tr>
<td>Rx</td>
<td>- Ethinyl estradiol 35 mcg/Norelgestromin 150 mcg <em>(Xulane, Zafemy)</em></td>
</tr>
<tr>
<td></td>
<td>- <strong>TWIRLA</strong> (Ethinyl estradiol 30 mcg/Levonorgestrel 120 mcg)</td>
</tr>
</tbody>
</table>

**Barrier Methods**

**The IOM Recommended as a Preventive Service for Women**
The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.²

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

---

*See disclaimer on last page for more information.*

². Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
## Barrier Methods

**CVS Caremark Recommendation**
- Females or members capable of pregnancy
- Quantity limit (1/300 days)
- Rx

**Product Description***
Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/RED)* have no generic available and are recommended for coverage.
- Cervical Caps
  - FEMCAP
- Diaphragms
  - CAYA
  - MILEX WIDE-SEAL
  - OMNIFLEX COIL SPRING SILICONE

## OTC—Contraceptives

**The IOM Recommended as a Preventive Service for Women**
The full range of FDA-approved contraceptive methods, sterilization procedures, and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.  

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

**CVS Caremark Recommendation**
- Females or members capable of pregnancy
- OTC (requires prescription)

**Product Description***
Brand names in *italics* and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in *(BOLD/RED)* have no generic available and are recommended for coverage.
- Female Condoms
  - FC-2
- Spermicides
  - Nonoxynol-9 Gel 4% *(Conceptrol Gel 4%, VCF Vaginal Contraceptive Gel)*
  - ENCORE VAGINAL SUPPOSITORIES
  - GYNOL II GEL 3%
  - SHUR-SEAL GEL 2%
  - VCF VAGINAL FILM 28%
  - VCF VAGINAL FOAM 12.5%
- Vaginal Sponge
  - TODAY *(Nonoxynol-9)*

*See disclaimer on last page for more information.

2. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G  093022
## Vaginal pH Modulators

### The IOM Recommended as a Preventive Service for Women

The full range of FDA-approved contraceptive methods, sterilization procedures and patient education and counseling for women with reproductive capacity. FDA-approved OTC contraceptive methods are also recommended if prescribed for a woman by her health care provider.²

CVS Caremark suggests a plan consider the following pharmacy related recommendations when developing its coverage under these provisions.

CVS Caremark notes that previous HHS guidance enables plans to apply reasonable medical management techniques when developing Preventive Services coverage.

These Women’s Health Preventive Services recommendations are an addendum to the initial CVS Caremark Preventive Services recommendations issued in October 2010.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>Product Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members capable of pregnancy</td>
<td>Brand names in <em>italics</em> and in parentheses are for reference only. Only generics and single-source brands are recommended for coverage without cost sharing. Brand names in [(BOLD/RED)] have no generic available and are recommended for coverage.</td>
</tr>
<tr>
<td>• Rx</td>
<td></td>
</tr>
<tr>
<td>• Generics and single-source brands</td>
<td>• <strong>PHEXXI</strong> (lactic acid 1.8%, citric acid 1% and potassium bitartrate 0.4% vaginal gel)</td>
</tr>
<tr>
<td>• Brands until generics become available</td>
<td></td>
</tr>
</tbody>
</table>

### Primary Prevention of Breast Cancer

### Medications for Risk Reduction of Primary Breast Cancer in Women

The USPSTF recommends that clinicians engage in shared, informed decision-making with women who are at increased risk for breast cancer, about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene or aromatase inhibitors.

<table>
<thead>
<tr>
<th>CVS Caremark Recommendation</th>
<th>GPI Description*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Females or members at increased risk of breast cancer</td>
<td>• Anastrozole tab 1 mg</td>
</tr>
<tr>
<td>• Age limit ≥ 35</td>
<td>• Exemestane tab 25 mg</td>
</tr>
<tr>
<td>• No prior authorization³</td>
<td>• Raloxifene HCl tab 60 mg</td>
</tr>
<tr>
<td>• Generic only</td>
<td>• Tamoxifen citrate tab 10 mg (base equiv) &amp; 20 mg (base equiv)</td>
</tr>
<tr>
<td>• Rx</td>
<td></td>
</tr>
</tbody>
</table>

---

2. Regardless of OTC status a prescription is required for coverage. Emergency contraception recommendation includes OTC products referenced in the IOM report.  
3. May be subject to certification process.  
*See disclaimer on last page for more information.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022
Optional Preventive Service
Medication-Assisted Treatment (MAT) for Substance Use Disorder

Introduction
Medication Assisted Treatment of Substance Use Disorder – or MAT – is an important tool to help reduce opioid misuse. MAT medications, including buprenorphine, buprenorphine-naloxone and naltrexone, are used in the treatment of opioid use disorders. In an effort to enhance access to MAT, CVS Caremark recommends coverage of three medications used in MAT as an optional preventive service, to be available at no member cost share.

Optional MAT for Substance Use Disorder

In April 2017, the Department of HHS detailed a five-point opioid strategy. A key tenet of their strategy was to “Improve access to prevention, treatment, and recovery support services to prevent the health, social, and economic consequences associated with opioid addiction and to enable individuals to achieve long-term recovery.”

While MAT for Substance Use Disorder is not a required preventive service for ACA non-grandfathered plans, CVS Caremark recommends coverage of these drugs at no member cost share as a benefit enhancement.

CVS Caremark Recommendation

• Generic only
• Rx
• To enhance access:
  – No prior authorization
  – No quantity limits

GPI Description*

• Buprenorphine sublingual tab 2 mg, 8 mg
• Buprenorphine-naloxone sublingual tab 2 mg-0.5 mg, 8 mg-2 mg
• Naltrexone tab 50 mg

4. Client specific utilization management may apply.
*Products listed may be updated periodically.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. This document contains CVS Caremark recommendations to assist clients in making ACA-compliant preventive services coverage decisions as required under federal law. In addition to federal requirements, some clients may be subject to more stringent state requirements. Clients must evaluate applicable state requirements and notify CVS Caremark of any coverage modifications necessary to comply with such requirements.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-21204G 093022